Cohance Lifesciences expects revenue, EBITDA bottom in Q1 FY27; Stock recovers from lows

Shares of Cohance Lifesciences Ltd. declined on Wednesday, May 13, even as it saw a sequential recovery in the business. The stock fell as much as 8% in early trade before paring some of those losses.

Umang Vohra, who took over the executive chairman and group CEO roles from May 1, joined the company's post-earnings call. He said by the end of the financial year 2027, he aims to build a strategic blueprint of growth.

The company said FY26 was a transition year and the fourth quarter earnings were in line its guidance. FY27 is expected to be a year of growth.

The company has guided for growth to return from the second half of FY27. It said the first quarter is likely to be the low point for both revenues and EBITDA.

Cohance Lifesciences said business is moving towards the bottoming out phase with recovery from the second half of FY27 onwards.

It is also expecting EBITDA improvement in the second half, driven by volume recovery, customer conversions, etc.

Cohance In Q4

The company reported a profit of ₹8.31 crore in the fourth quarter, down 71.4% sequentially and down 92.9% from the previous year.

Its revenue increased 13.7% sequentially to ₹619.12 crore but was down 26.3% from the previous year's ₹840 crore.

The company's earnings before interest, tax, depreciation and amortization (EBITDA) was up 3.5% at ₹98.68 crore from the last quarter but was down 56.9% from last year's ₹229.2 crore.

Its margins contracted to 15.9% from 17.5% sequentially and 27.3% in the year-ago period.

Shares of Cohance Lifesciences are recovering from the lows of the day, currently trading 2.9% lower at ₹470.7. The stock has risen 31% over the last one month and is among the best performing names in the broader market for the year.

Also Read: Berger Paints shares jump 8% after double-digit volume growth, gross margins at 12-quarter high